Pregabalin Capsule
Product Images NDC 71610-799

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-799). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0799 30)

Pregabalin 75 mg oral capsules packaging label showing a bottle containing 30 capsules. The label includes the NDC 71610-0799-30, storage instructions between 20-25 degrees Celsius, and dispensing information. It is labeled by Aphena Pharma Solutions - Tennessee, LLC, Cookeville, TN, with a warning about potential fetal harm and restriction to prescription use only.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure of pregabalin showing its molecular arrangement including an amino group (NH2) and a carboxyl group (CO2H) attached to a branched carbon chain.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. Four lines represent groups taking Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph illustrates patient improvement trends by dosage level and placebo.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. Two lines compare Pregabalin 100 mg three times a day and placebo, illustrating higher patient improvement rates with Pregabalin across various pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin 04)

Line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day, compared with placebo. The graph illustrates higher patient improvement percentages with increasing Pregabalin doses compared to placebo across pain improvement percentages.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and a placebo, with respective lines representing improvement trends across a range of pain improvement percentages from 0 to 100%.*

FDA Label Image

Figure 5 (Pregabalin 06)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph compares pain improvement outcomes across these three groups.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart comparing responder rates (%) in two studies (E1 and E3) for Pregabalin doses versus placebo. Study E1 shows increasing responder rates from placebo (14%) up to 51% at 600 mg/day. Study E3 shows responder rates of 9% for placebo, 43% for 300 mg/day BID, and 49% for 600 mg/day TID. X-axis labels dosing groups and sample sizes; y-axis shows responder rate percentage.*

FDA Label Image

Figure 7 (Pregabalin 08)

A dose-response chart showing median percent change from baseline in seizure reduction versus dose in mg/day of pregabalin. Four studies are compared (E1 BID, E2 TID, E3 BID, E3 TID) with plotted data points indicating significant p-values for seizure reduction at various doses compared to placebo.*

FDA Label Image

Figure 9 (Pregabalin 09)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline with different pregabalin doses and a placebo. Four lines represent pregabalin 600 mg, 450 mg, and 300 mg daily doses, and placebo, showing trends of patient improvement across pain improvement percentages.*

FDA Label Image

Figure 10 (Pregabalin 10)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR over time in days between Pregabalin and Placebo groups. The solid line represents Pregabalin and shows a higher percentage of subjects without LTR over 180 days compared to the dashed line for Placebo.*

FDA Label Image

Figure 11 (Pregabalin 11)

A Kaplan-Meier survival curve chart illustrating the percent of subjects improved from baseline to Week 12 BOCF. The y-axis shows the percent of subjects improved (0-100%), and the x-axis shows the percent improved over time intervals up to 100. Two curves are displayed: a solid line for Pregabalin and a dashed line for Placebo, with Pregabalin showing higher percentages of improvement throughout the timeline.*

FDA Label Image

Figure 12 (Pregabalin 12)

A line graph comparing the percent of subjects improved over time from baseline to week 16, showing results for Pregabalin versus Placebo. The horizontal axis represents percent improved from baseline to week 16, and the vertical axis represents percent of subjects improved, with both solid and dashed lines illustrating outcomes for Pregabalin and Placebo, respectively.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.